Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from CDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches

Drug Metabolism and Disposition

Volumn 28, Issue 12, 2000, Pages 1493-1504

  Venkatakrishnan, Karthik ^a,b   Von Moltke, Lisa L ^a,b   Court, Michael H ^a,b   Harmatz, Jerold S ^a,b   Crespi, Charles L ^c   Greenblatt, David J ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME C OXIDASE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; LYMPHOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ALGORITHMS; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DATA INTERPRETATION, STATISTICAL; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOCHEMISTRY; ISOENZYMES; LYMPHOCYTES; MALE; MICROSOMES, LIVER; PROTEINS; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 0033674502     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
2. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
3. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
4. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
5. Further characterization of the expression in liver and catalytic activity of CYP2B6
6. The measurement of difference spectra: Application to the cytochromes of microsomes
7. CYP2B6 mediates the in vitro biotransformation of bupropion to hydroxybupropion: Potential drug interactions with other antidepressants
8. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
9. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes
10. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
11. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs
12. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
13. Unchanged CYP 3A expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes
14. Hepatic triphosphopyridine nucleotide cytochrome c reductase: Isolation, characterization and kinetic studies
15. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions
16. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
17. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources
18. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
19. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: Sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines
20. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
21. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
22. Cytochrome P450 reconstitution systems
23. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
24. Scaling drug biotransformation data from cDNA-expressed CYP to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism
25. Monospecific antipeptide antibody to cytochrome P-450 2B6
26. Five distinct human cytochromes mediate amitriptyline N-demethylatlon in vitro: Dominance of CYP 2C19 and 3A4
27. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: Validation of the high-affinity component as an index of CYP1A2 activity
28. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
29. CYP2C9 is a principal low-affinity phenacetin O-deethylase: Fluvoxamine is not a specific CYP1A2 inhibitor
30. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low-affinity): Implications for interactions with enzyme-inducing drugs
31. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
32. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine
33. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
34. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole
35. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes
36. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples
37. In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors